Orion OYJ (OTCMKTS:ORINY – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Orion OYJ to related businesses based on the strength of its analyst recommendations, earnings, valuation, risk, profitability, dividends and institutional ownership.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Orion OYJ and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Orion OYJ | 0 | 1 | 0 | 1 | 3.00 |
| Orion OYJ Competitors | 7845 | 13798 | 25818 | 1039 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 23.64%. Given Orion OYJ’s competitors higher possible upside, analysts clearly believe Orion OYJ has less favorable growth aspects than its competitors.
Earnings and Valuation
This table compares Orion OYJ and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Orion OYJ | $2.14 billion | $566.04 million | 21.36 |
| Orion OYJ Competitors | $18.73 billion | $3.24 billion | 559.25 |
Orion OYJ’s competitors have higher revenue and earnings than Orion OYJ. Orion OYJ is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Dividends
Orion OYJ pays an annual dividend of $0.36 per share and has a dividend yield of 0.6%. Orion OYJ pays out 13.3% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.3% and pay out 49.2% of their earnings in the form of a dividend.
Risk and Volatility
Orion OYJ has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Comparatively, Orion OYJ’s competitors have a beta of -0.04, suggesting that their average share price is 104% less volatile than the S&P 500.
Profitability
This table compares Orion OYJ and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Orion OYJ | 30.25% | 54.09% | 33.33% |
| Orion OYJ Competitors | -2,398.26% | -203.62% | -15.08% |
Insider and Institutional Ownership
32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Orion OYJ competitors beat Orion OYJ on 8 of the 15 factors compared.
About Orion OYJ
Orion Oyj is a Finnish pharmaceutical company that develops, manufactures and markets medicines for human and veterinary use. Its portfolio includes prescription and over-the-counter medicines, as well as active pharmaceutical ingredients supplied to other pharmaceutical companies. Founded in 1917 and headquartered in Espoo, Finland, Orion has a long history in the pharmaceutical industry. The company focuses on areas including oncology, neurology and respiratory diseases, and develops some products in collaboration with international pharmaceutical partners.
Receive News & Ratings for Orion OYJ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orion OYJ and related companies with MarketBeat.com's FREE daily email newsletter.
